Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al.
McCabe
Christopher
C
Tsuchiya
Aki
A
Claxton
Karl
K
Raftery
James
J
D003362:Cost-Benefit Analysis; D005060:Europe; D006291:Health Policy; D006801:Humans; D009965:Orphan Drug Production / Q000191:economics*; D013673:Technology Assessment, Biomedical; D014481:United States